Status:

UNKNOWN

Minimally Invasive Tricuspid Surgery vs Medical Treatment for Severe TR

Lead Sponsor:

Shanghai Zhongshan Hospital

Conditions:

Tricuspid Regurgitation

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

Late tricuspid regurgitation (TR) is a common complication after left-sided valve surgery (LSVS), which usually progresses slowly and results in right heart failure at terminal stage. Over the past 3 ...

Detailed Description

In this multi-center randomized controlled trial, patients with severe TR after LSVS will be recruited. The patients will be randomly assigned to surgery plus medical therapy (surgery group) or medica...

Eligibility Criteria

Inclusion

  • Severe tricuspid regurgitation, as assessed by the clinical site echocardiographer using the transthoracic echocardiography.
  • A history of LSVS, including one or multiple procedures of aortic and/or mitral valve repair and/or replacement.
  • Left ventricular ejection fraction (LVEF) \>45%, systolic pulmonary artery pressure \<60 mmHg with pulmonary vascular resistance \<6 woods unit.
  • Age ≥ 18 years.
  • Able to sign Informed Consent forms.

Exclusion

  • TR due to: infective endocarditis, congenital tricuspid valve malformation, secondary to correction of congenital heart disease.
  • Left-sided valve dysfunction or coronary artery disease requiring concomitant procedures.
  • Prior surgical or percutaneous tricuspid valve intervention.
  • Evidence of an acute myocardial infarction in the prior 90 days
  • Contraindications to cardiopulmonary bypass or the expected operative mortality \>30% (calculated by the Society of Thoracic Surgeons score or the EuroSCORE II).
  • Any comorbidity with life expectancy \<2 years
  • Recent history of psychiatric disease (including drug or alcohol abuse) that is likely to impair compliance with the study protocol.
  • Pregnancy at the time of randomization.

Key Trial Info

Start Date :

May 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2024

Estimated Enrollment :

330 Patients enrolled

Trial Details

Trial ID

NCT04339192

Start Date

May 1 2020

End Date

June 1 2024

Last Update

April 9 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China, 200032